Literature DB >> 14630715

Transcriptional regulation of human sodium/iodide symporter gene: a role for redox factor-1.

Cinzia Puppin1, Franco Arturi, Elisabetta Ferretti, Diego Russo, Rosario Sacco, Gianluca Tell, Giuseppe Damante, Sebastiano Filetti.   

Abstract

The transcriptional regulation of the human sodium/iodide symporter (NIS) gene in normal and transformed thyroid cells is a crucial issue in attempting to restore iodide uptake and use radioiodine as a therapeutic treatment of thyroid cancer. Previous investigations have shown that the multifunctional protein apurinic apyrimidinic endonuclease/redox factor 1 (APE/Ref-1) plays an important role in regulation of thyroid-specific gene transcription. In this study, we investigated the effects of APE/Ref-1 on human NIS promoter activity. Cotransfection experiments performed in nonthyroid HeLa cells demonstrated that APE/Ref-1 exerts both PAX8-dependent and PAX8-independent effects. In fact, in the absence of PAX8, overexpression of APE/Ref-1 enhanced NIS promoter activity 2-fold. When the expression plasmid of APE/Ref-1 was transfected together with an expression plasmid for PAX8, a strong cooperative effect was detected with an increase of NIS promoter activity 9-fold over control. The PAX8-independent effect of APE/Ref-1 was specific for the NIS promoter, resulting not present for the promoter of the thyroperoxidase (TPO) gene. It was, at least in part, due to the up-regulation of the transcriptional activity of the ubiquitous factor early growth response-1 (Egr-1). In the thyroid tumor cell lines TPC-1 and B-CPAP, APE/Ref-1 was not effective by itself, and it also failed to increase PAX8 stimulation on NIS promoter activity. These data demonstrate a role for APE/Ref-1 protein in the transcriptional regulation of NIS gene expression by itself and in cooperation with PAX8. However, restoring the PAX8-APE/Ref-1 expression in tumor cells may not be sufficient to obtain adequate levels of NIS gene expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14630715     DOI: 10.1210/en.2003-1250

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

Review 1.  The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.

Authors:  Takahiko Kogai; Gregory A Brent
Journal:  Pharmacol Ther       Date:  2012-06-29       Impact factor: 12.310

Review 2.  Redox Homeostasis in Thyroid Cancer: Implications in Na+/I- Symporter (NIS) Regulation.

Authors:  Juliana Cazarin; Corinne Dupuy; Denise Pires de Carvalho
Journal:  Int J Mol Sci       Date:  2022-05-30       Impact factor: 6.208

Review 3.  Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma.

Authors:  June-Key Chung; Hye Won Youn; Joo Hyun Kang; Ho Young Lee; Keon Wook Kang
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

4.  The sodium/iodide symporter NIS is a transcriptional target of the p53-family members in liver cancer cells.

Authors:  F Guerrieri; S Piconese; C Lacoste; V Schinzari; B Testoni; Y Valogne; S Gerbal-Chaloin; D Samuel; C Bréchot; J Faivre; M Levrero
Journal:  Cell Death Dis       Date:  2013-09-19       Impact factor: 8.469

5.  HEX expression and localization in normal mammary gland and breast carcinoma.

Authors:  Cinzia Puppin; Fabio Puglisi; Lucia Pellizzari; Guidalberto Manfioletti; Marta Pestrin; Maura Pandolfi; Andrea Piga; Carla Di Loreto; Giuseppe Damante
Journal:  BMC Cancer       Date:  2006-07-19       Impact factor: 4.430

6.  Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene.

Authors:  Ivan Presta; Franco Arturi; Elisabetta Ferretti; Tiziana Mattei; Daniela Scarpelli; Emanuele Tosi; Angela Scipioni; Marilena Celano; Alberto Gulino; Sebastiano Filetti; Diego Russo
Journal:  BMC Cancer       Date:  2005-07-19       Impact factor: 4.430

Review 7.  Targeted Radionuclide Therapy of Human Tumors.

Authors:  Sergey V Gudkov; Natalya Yu Shilyagina; Vladimir A Vodeneev; Andrei V Zvyagin
Journal:  Int J Mol Sci       Date:  2015-12-28       Impact factor: 5.923

8.  Nevirapine Increases Sodium/Iodide Symporter-Mediated Radioiodide Uptake by Activation of TSHR/cAMP/CREB/PAX8 Signaling Pathway in Dedifferentiated Thyroid Cancer.

Authors:  Hongxia Shang; Junyu Zhao; Jinming Yao; Huanjun Wang; Jianjun Dong; Lin Liao
Journal:  Front Oncol       Date:  2020-03-31       Impact factor: 6.244

Review 9.  Strategies for Radioiodine Treatment: What's New.

Authors:  Clotilde Sparano; Sophie Moog; Julien Hadoux; Corinne Dupuy; Abir Al Ghuzlan; Ingrid Breuskin; Joanne Guerlain; Dana Hartl; Eric Baudin; Livia Lamartina
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

Review 10.  Radioiodine therapy in differentiated thyroid cancer: the first targeted therapy in oncology.

Authors:  June-Key Chung; Gi Jeong Cheon
Journal:  Endocrinol Metab (Seoul)       Date:  2014-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.